Recent Price Performance and Market Sentiment
Hikal Ltd has experienced a notable decline in its share price, hitting a new 52-week low of ₹207.8 on 14-Jan. The stock opened with a gap down of 2.4% and has underperformed its sector by 0.36% on the day. This marks the fifth consecutive day of losses, during which the stock has fallen by 5.24%. Such a consistent downward trend indicates persistent negative sentiment among investors.
Moreover, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook. Investor participation has also waned, with delivery volumes on 13-Jan dropping by over 32% compared to the five-day average, suggesting reduced buying interest and liquidity pressures despite the stock’s adequate tradability for moderate trade sizes.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Fundamental Weaknesses Driving the Decline
Hikal’s share price decline is underpinned by significant fundamental challenges. Over the past year, the stock has delivered a negative return of 42.19%, starkly contrasting with the Sensex’s 9.00% gain during the same period. This underperformance extends over longer horizons as well, with the stock falling 47.51% over three years, while the benchmark index rose by 38.37%. Although the five-year return remains positive at 20.89%, it lags considerably behind the Sensex’s 68.16% growth.
The company’s profitability metrics reveal deeper concerns. Operating profits have contracted at a compounded annual growth rate of -16.24% over the last five years, signalling sustained operational challenges. Earnings per share have plummeted by 320.54%, culminating in very negative quarterly results declared in September 2025. The latest quarterly profit after tax stood at a loss of ₹34.90 crore, a dramatic fall compared to previous quarters.
Return on capital employed (ROCE) remains subdued at 4.1%, with the half-year figure even lower at 4.44%, indicating inefficient capital utilisation. The company’s ability to service debt is also strained, with a high Debt to EBITDA ratio of 2.51 times and an operating profit to interest coverage ratio of just 0.48 times in the latest quarter. These factors collectively highlight the company’s weak financial health and low profitability per unit of shareholder funds, as reflected in an average return on equity of 8.00%.
Valuation and Investor Considerations
Despite these challenges, Hikal trades at an attractive valuation relative to its peers, with an enterprise value to capital employed ratio of 1.8. This discount to historical peer valuations may offer some appeal to value-oriented investors. However, the steep decline in profits by 86.2% over the past year and the company’s ongoing negative earnings results temper any optimism.
Given the weak long-term fundamentals, poor recent earnings performance, and continued share price underperformance relative to broader indices and sector benchmarks, the stock remains under pressure. The majority shareholding by promoters has not translated into improved operational or financial outcomes, further dampening investor confidence.
Holding Hikal from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Why Hikal Ltd Is Falling
In summary, Hikal Ltd’s share price decline on 14-Jan and over recent periods is primarily driven by its deteriorating financial performance and weak profitability metrics. The company’s inability to generate consistent operating profits, coupled with a sharp fall in earnings and poor debt servicing capacity, has eroded investor confidence. This is reflected in the stock’s sustained underperformance against the Sensex and sector peers, hitting new lows and trading below all major moving averages.
While the stock’s valuation appears attractive on certain metrics, the fundamental weaknesses and negative earnings trajectory suggest continued caution. Investors are likely to remain wary until there is clear evidence of a turnaround in profitability and operational efficiency.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
